Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 AUD | 0.00% | 0.00% | +25.00% |
Feb. 25 | Bio-Gene Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Jan. 19 | Bio-gene Technology Secures R&D Tax Rebate for Fiscal Year 2023 | MT |
Sales 2022 | 446K 290K | Sales 2023 | 149K 97.14K | Capitalization | 13.88M 9.03M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.3M | Net income 2023 | -3M -1.95M | EV / Sales 2022 | 37.7 x |
Net cash position 2022 | 6.34M 4.13M | Net cash position 2023 | 2.99M 1.95M | EV / Sales 2023 | 72.9 x |
P/E ratio 2022 |
-6.84
x | P/E ratio 2023 |
-4.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.93% |
Current month | +4.17% | ||
1 month | +17.19% | ||
3 months | +29.31% | ||
6 months | +7.14% | ||
Current year | +25.00% |
Managers | Title | Age | Since |
---|---|---|---|
Tim Grogan
CEO | Chief Executive Officer | - | 23-08-27 |
Peter May
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sarah Driessens
LAW | General Counsel | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter May
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Guthrie
BRD | Director/Board Member | - | 21-04-25 |
Alex Ding
CHM | Chairman | - | 23-05-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 0.075 | 0.00% | 1,309 |
24-04-19 | 0.075 | 0.00% | 41,506 |
24-04-17 | 0.075 | 0.00% | 47,650 |
24-04-16 | 0.075 | +4.17% | 48,150 |
Delayed Quote Australian S.E., April 22, 2024 at 02:10 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.00% | 9.79M | |
+15.15% | 38.56B | |
-.--% | 11.01B | |
-6.98% | 7.32B | |
+6.48% | 6.72B | |
-1.54% | 6.16B | |
-3.81% | 5.63B | |
+28.59% | 5.08B | |
-11.52% | 5.23B | |
+18.80% | 4.44B |
- Stock Market
- Equities
- BGT Stock